Low testosterone levels

Mark Cuban Cost Plus Drug Company ( MCCPDC ) has announced a partnership with male fertility and sexual healthcare company Posterity Health to provide males access to medications to treat infertility, sexual dysfunction and low testosterone. Posterity Health is a digital male fertility clinic providing access to reproductive urologists who diagnose and treat sexual health and male fertility issues. The company offers sperm cryopreservation, in-clinic or in-home fertility testing, vasectomy and vasectomy reversal. "We started Cost Plus Drugs to make medications more affordable and accessible. In addition, we hope to make people healthier and to encourage those impacted by medical conditions to take action," Mark Cuban, founder of Cost Plus Drugs, said in a statement. "It is time to break the stigma around male fertility and men’s sexual health. Treatment for these conditions is often life-changing. Working together with Posterity Health, we can help more men receive the care and treatment they need to become healthier fathers." THE LARGER TREND Earlier this month, MCCPDC announced it is working with Coherus Biosciences to sell Yusimry, a biosimilar version of top-seller Humira, at a discounted price. The medication treats psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn’s disease and other conditions. Cuban expressed his excitement about the partnership to MobiHealthNews in an email, saying, "Coherus's Yusimry is a game changer. Having an alternative to Humira that is affordable will improve the lives of patients everywhere." In April the company announced a collaboration with Seattle-based Zócalo Health , a virtual healthcare service for Latino patients, meant to expand Zócalo members' access to lower-cost prescription medication. The company has developed numerous other partnerships, including with California-based EmsanaRx and Tennessee-based RxPreferred Benefits . It also collaborates with diabetes and chronic disease management company Diathrive Health , and with cancer care support company OncoPower . MCCPDC was integrated into Rightway Health 's platform, so allowing the pharmacy benefit manager's members access to MCCPDC. Last year, MCCPDC announced its first health plan partnership with Capital Blue Cross , which allows Capital's members to use their insurance cards at MCCPDC directly.

NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testosterone deficiency in men with certain medical conditions. Clarus has filed a series of motions with the Court seeking to ensure the continuation of normal operations while on this path. Clarus believes that it has sufficient financial resources to meet its operational and financial obligations to patients, healthcare providers, suppliers, and employees through the Chapter 11 process. In addition, scaled-back efforts will continue to support commercialization of JATENZO. “After thoroughly exploring our strategic options in a robust process conducted by the Capital Structure Advisory team at Raymond James, and in light of the extremely challenging financial markets, Clarus’ Board of Directors and its senior management team have unanimously concluded that a structured sale process represents the best possible solution for Clarus and its stakeholders,” said Dr, Robert Dudley, CEO of Clarus. “We strongly believe that JATENZO has the potential to be a valuable product for the treatment of men with testosterone deficiency and, with continued commercialization efforts, to capture increasing market share over time. Unfortunately, Clarus is no longer in a tenable financial position to provide such efforts nor remain a viable entity.” The proposed bidding procedures, if approved by the Court, would allow interested parties to submit binding offers to acquire substantially all of Clarus’ assets (i.e., principally JATENZO and related assets), which would be purchased free and clear of Clarus’ indebtedness and certain liabilities. Interested parties could include both strategic and financial buyers, for whom substantial due diligence materials are available. Additional information about this process and proposed asset sale, as well as other documents related to the Chapter 11 proceedings, is available through Clarus’ claims agent, Stretto, Inc.. Clarus’ legal counsel is Goodwin Procter, LLP and Potter Anderson & Corroon LLP, and its investment banker is Raymond James & Associates, Inc. Clarus has also named Lawrence Perkins of Sierra Constellation Partners, LLC as Chief Restructuring Officer during the Chapter 11 process. Interested parties should contact Geoffrey Richards (Geoffrey.Richards@RaymondJames.com) and Simon Wein (Simon.Wein@RaymondJames.com) at Raymond James for additional information related to the auction and sale process and for access to due diligence materials. Clarus filed the voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the District of Delaware, Case No. 22-10845. About Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen-based medicines. Clarus Therapeutics’ first commercial product is JATENZO (testosterone undecanoate capsules; C-III). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow Clarus on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).